Search research articles
Contact Us
Filters
Showing results (111-120 of 194) with videos related to
Page
of 20
Sort By:
Proceedings of the National Academy of Sciences of the United States of America
|
October 19, 2011
Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing
Tom Walsh, Silvia Casadei, Ming K Lee, et al.
Oncotarget
|
November 8, 2017
Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer
Jung-Min Lee, John L Hays, Victoria L Chiou, et al.
The Lancet. Oncology
|
January 24, 2018
Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study
Jung-Min Lee, Jayakumar Nair, Alexandra Zimmer, et al.
Gynecologic Oncology
|
December 21, 2021
Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial
Carol Aghajanian, Elizabeth M Swisher, Aikou Okamoto, et al.
JAMA Oncology
|
February 6, 2016
Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma
Elizabeth M Swisher, Maria I Harrell, Barbara M Norquist, et al.
Cancer Prevention Research (Philadelphia, Pa.)
|
May 26, 2016
Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence
Mark E Sherman, Ronny I Drapkin, Neil S Horowitz, et al.
Molecular Cancer Therapeutics
|
October 3, 2019
Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations
Pyoung Hwa Park, Tomomi M Yamamoto, Hua Li, et al.
JCO Precision Oncology
|
May 14, 2026
Homozygous Loss of Recombination Repair Genes and Poly ADP-Ribose Polymerase Inhibitor Benefit for Patients With Ovarian Cancer
Elizabeth M Swisher, Gottfried Konecny, Joshua Cohen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 19, 2013
Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas
Kathryn P Pennington, Tom Walsh, Maria I Harrell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 2021
Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513
E Gabriela Chiorean, Katherine A Guthrie, Philip A Philip, et al.
Page
of 20
Search research articles
Search
Showing results (111-120 of 194) with videos related to
Sort By:
Page
of 20
Proceedings of the National Academy of Sciences of the United States of America
|
October 19, 2011
Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing
Tom Walsh, Silvia Casadei, Ming K Lee, et al.
Oncotarget
|
November 8, 2017
Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer
Jung-Min Lee, John L Hays, Victoria L Chiou, et al.
The Lancet. Oncology
|
January 24, 2018
Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study
Jung-Min Lee, Jayakumar Nair, Alexandra Zimmer, et al.
Gynecologic Oncology
|
December 21, 2021
Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial
Carol Aghajanian, Elizabeth M Swisher, Aikou Okamoto, et al.
JAMA Oncology
|
February 6, 2016
Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma
Elizabeth M Swisher, Maria I Harrell, Barbara M Norquist, et al.
Cancer Prevention Research (Philadelphia, Pa.)
|
May 26, 2016
Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence
Mark E Sherman, Ronny I Drapkin, Neil S Horowitz, et al.
Molecular Cancer Therapeutics
|
October 3, 2019
Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations
Pyoung Hwa Park, Tomomi M Yamamoto, Hua Li, et al.
JCO Precision Oncology
|
May 14, 2026
Homozygous Loss of Recombination Repair Genes and Poly ADP-Ribose Polymerase Inhibitor Benefit for Patients With Ovarian Cancer
Elizabeth M Swisher, Gottfried Konecny, Joshua Cohen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 19, 2013
Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas
Kathryn P Pennington, Tom Walsh, Maria I Harrell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 2021
Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513
E Gabriela Chiorean, Katherine A Guthrie, Philip A Philip, et al.
Page
of 20